DDInter300 DDInter1180
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Cariprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amyl Nitrite
Cariprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Cariprazine {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Cariprazine {u} may lead to a major life threatening interaction when taken with {v} Morphine
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Cariprazine may lead to a major life threatening interaction when taken with Cobicistat
Cariprazine may lead to a major life threatening interaction when taken with Morphine